Research Reports

Pricing and Reimbursement in Key Asia Pacific Markets

Mon, 23 Feb 2009 14:41:10 -0500

Introduction

With the Asia-Pacific markets growing rapidly, they are becoming increasingly attractive for Pharma to enter. However, a number of key P&R developments and reforms are set to change the healthcare environment in the next few years, as healthcare is made more accessible to the poor and elderly.

Scope

*Insight into pricing and reimbursement strategies in Australia, Singapore, China and Hong Kong

*Analysis of drivers and barriers for entering Australia, Singapore, China and Hong Kong

*Overview of healthcare systems in Australia, Singapore, China and Hong Kong

*Identification of trends shaping national P&R strategies and their impact on branded Pharma

Highlights

In Australia, a high level of evidence is needed to show clinical and cost effectiveness, thus clearly pointing to a barrier for entering the Australian market. It is essential that a new medicine is cost effective against the standard of care, therefore solid head-to-head clinical trial data must be presented to have a successful listing.

Recent changes by the Chinese National Development and Reform Commission (NDRC) means that the financial rewards for the multinationals will be jeopardized. The pricing authority has planned another round of price reductions, but for the first time, this will also affect imported drugs.

Singapore's affluent population translates into high per capita spending on healthcare and a preference for branded drugs. Its healthcare financing system based on co-payments discourages excessive consumption and acts as a measure of cost-containment.

Reasons to Purchase

*Understand the recent changes in the P&R environment in the key Asia-Pacific markets

*Analyze recent trends in healthcare in Asia-Pacific and the impact on branded pharma

*In-depth and up to date information on P&R regulations through interviewing local industry executives

Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success

Mon, 23 Feb 2009 14:38:47 -0500

Delivery Mechanisms for Large Molecule Drugs
Successes and failures of leading technologies and key drivers for market success

Emerging drug delivery technologies aim to improve measures of safety, efficacy, convenience and compliance in both new and existing drug candidates and products. For currently marketed products, reformulations with new delivery technologies will extend the period of patent protection. New formulas will be key to boosting sales volume of large molecule products in chronic diseases where patient compliance surrounding dosing strategies and ease of administration are limitations on market growth. In R&D pipelines, novel applications of delivery technologies will expose new methods to reformulate failed or discontinued drugs and mask their unfavorable effects, expanding the market of potential drug candidates.
‘Delivery Mechanisms for Large Molecule Drugs' is a report published by Business Insights that examines the future of the drug delivery technologies market, and the short, mid, and long-term growth dynamics which will underpin investment decisions. This report will measure the performance of leading drug delivery technologies applied within clinical R&D pipelines and identify when specific therapy area populations are set to benefit from emerging innovations. The market success of new technologies is forecast by their ability to fulfill unmet medical need, the maturity of the technology in clinical application, and the level of commercial interest and investment landscape.

Key Findings

Nanotechnology will have the greatest impact on the drug delivery market. However, the immaturity of the technology is likely to delay marketed presence over the next 7-10 years.

Antibody fragmentation and PEGylation technologies are the leading targeted large molecule particle engineering formulas with marketed drug product presence. However, antibody fragments have suffered 33 candidate failures compared with 12 PEGylated products.

Active transdermal technologies have generated the greatest number of technologies and devices amongst large molecule delivery innovations, with 16 clinical and 8 preclinical drug/device combination products and 49 stand-alone devices.

Electronic delivery is set to have the greatest impact upon the device industry. Electronic device control is more advanced within the field of pulmonary delivery than transdermal delivery, with the average pulmonary-based product in early clinical phase I compared to late-stage preclinical investigation for transdermal. There are, however, 25 transmembrane electroporation technologies currently being developed,
in comparison to 12 for electronic active pulmonary delivery.

Use this report to...

• Understand the drivers of new delivery platform developments with this report's analysis of therapy area growth drivers, clinical development spend and unmet clinical need.
• Identify the risks and opportunities associated with emerging delivery technologies by measuring the risk potential and maturity of innovative platforms.
• Evaluate the latest developments in systemic targeting technologies by using this report's analysis of innovations and pipeline progress for the latest active and passive targeting techniques.
• Discover which technologies have the greatest potential within large molecule product markets in the future with this report's comparative analysis of growth metrics for leading platforms and an evaluation of their established clinical drug application.
• Assess recent innovations in pulmonary delivery technologies and needle-free
transdermal delivery with this report's analysis of clinical and preclinical developments and commercial potential.

Explore issues including...
High failure rates for new technologies. The high failure rates of drugs to which pioneering delivery techniques have been applied have made investors cautious.
Unknown clinical safety and efficacy profiles have made it harder to determine appropriate parameters for success in clinical application.
Immaturity of technologies. Many of the technology platforms profiled in this report are in the early stages of application to clinical drug candidates. Those that have achieved success in marketed drug candidates already have ‘next generation' alternatives in technology pipelines.
Unknown clinical pharmacokinetics. Many of these platforms remain in such an immature stage that they have yet to be applied to drug candidates. In vivo
experimental use in drug candidates can never accurately predict success once a technology has reached maturity. Even for those technologies with established use in R&D pipelines, long-term clinical efficacy remains unknown.
Regulation of the new technologies. While the clinical performance of new particle engineered drug molecules or active delivery devices remain unknown, regulatory bodies only have existing data-measure demands on which to benchmark their expectations. This framework will be shifted in line with emerging clinical performance datasets.

Discover...
• Which delivery technologies will have the greatest impact on the large molecule market in the short, mid, and long-term?
• How mature are the different delivery technologies and what is their pipeline presence in terms of application to R&D drugs?
• Will particle engineering technologies drive injectable formulas to dominate the market?
• Which therapy areas will benefit most from growth in the different technologies?
• How can the risk-profiles associated with clinical use be most effectively minimized?
• What are the leading novel platforms?
• Who are the targets for out-licensing and co-development of platforms for clinical use?
• What are the leading technology platforms within different classifications and how have they achieved their growth?

The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis

Mon, 23 Feb 2009 14:35:45 -0500

The Cardiovascular Market Outlook to 2013

The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer's Lipitor, Sanofi's Plavix and Lovenox, and Amgen's Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape.

‘The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis' is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report...

Some key findings from this report...
• Anti-hypertensives were the highest selling sub-therapeutic category in 2007, with global sales of $52.9bn. Norvasc was the leading anti-hypertensive, with sales of $3.3bn.

• The global market for anticoagulants will experience significant activity over the next two years with the introduction of new drugs including Boehringer Ingelheim's Pradaxa/Rendix, Bayer- Schering/J&J's Xarelto, BMS/Pfizer's apixaban and Eli Lilly/Daiichi's Effient.

• Crestor has been steadily gaining market share and positive JUPITER trial results will help to further improve its market position. The positive trial data is likely to result in recommended cholesterol treatment goals becoming lowered, and Crestor will be well positioned to capture more patients and expand the market.

• GlaxoSmithKline's (GSK) acquisition of Reliant Pharma will contribute to GSK having the highest growth amongst the leading players through to 2013. The addition of key drugs such as Lovaza to GSK's portfolio will drive this growth.

• The anti-arrhythmic market is expected to remain a relatively small opportunity, as drug therapy has significant limitations. Multaq from Sanofi-Aventis may become the therapeutic standard in the first-line treatment of chronic atrial fibrillation.

Top five reasons to order your copy today

• Assess patient potential, treatment trends and sales patterns across major cardiovascular diseases over the period 2007-13 within the subtherapy areas of hypertension, dyslipidemia, thrombosis and stroke.

• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of AstraZeneca, Amgen, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer and Sanofi-Aventis.

• Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.

• Compare the future prospects of key players and forecast sales of leading products across major indications to 2013 with this report's analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and strategy/growth assessments.

• Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...

• Leading cholesterol-lowering drugs show declining sales. Patent expirations have been off-setting positive drivers of growth including recent trial results that support aggressive LDL lowering in broader patient populations. The availability of generic simvastatin has resulted in increased therapeutic substitution and declining brand share.

• Stalling growth of leading hypertension drugs. Angiotensin receptor blockers or ARBs have become the most prescribed antihypertensive class. However after several years of gaining market, growth in the branded ARB category appears to be stalling. A number of studies have shown ARBs to be no more effective than generic ACE inhibitors, most recently the ONTARGET study published in April, 2008

• Novel oral anti-thrombotics threaten leading drugs. Novel drugs in the thrombosis market pipeline are expected to strongly compete with the current market leader Lovenox . The new drugs are orally formulated and are expected to substantially expand the market. Trial data has shown these drugs to be more efficacious without presenting a huge inrease in the risk of bleeding.

Your questions answered...
• Which indications will experience the greatest growth in the global cardiovascular market over the period 2008-13? • Which companies will become the key players in the cardiovascular area over the period 2009 -13?

• How have recent major product launches from companies such as Gilead and Novartis performed?

• What is the forecast market size and growth rate over the period 2008-2013 across the major cardiovascular indications?

• Which pipeline products offer the highest growth potential? • What will be the competitive landscape of hypertension, dyslipidemia, thrombosis, hematology and cardiac therapies in 2013?

Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment

Mon, 23 Feb 2009 14:30:56 -0500

Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment

The pharma outsourcing industry in China has experienced over 35% year on year growth in the past few years. Increasingly, the sophisticated service offer of multinational CROs/CMOs is being challenged by improving Chinese players importing Western expertise, experience and business models to this fast growth market. However, there are still wide variations in service quality and capability from domestic outsourcing providers and many pharma and biotechs in Western markets are still reluctant to transfer parts of the drug development process to China.

Their concerns largely stem from issues around intellectual property rights (IPR), copyright infringements and counterfeiting. At both a corporate and governmental level, this weakness has been recognized and several key changes have been made to Chinese patent law, while service providers have also sought to improve their IPR protection processes and service standards. Nonetheless, key differences in secure IPR protection standards and service capability remain among domestic players.

‘Intellectual Property and Outsourcing in China' is a new report published by Business Insights that explores the expanding pharma outsourcing market in China to discover how large pharma, small-sized pharma and biotech can most effectively utilize the country's service offerings and capabilities. It examines the latest outsourcing trends and service provisions across all stages of the drug discovery process and profiles the leading domestic CRO/CMOs. This report provides an in-depth investigation of the changing IPR protection landscape in China and analyses the strategies which can minimize infringement risks. Case studies are used to illustrate the success of recent CRO/CMO partnerships with Western companies and key criteria for selecting suitable service providers are also identified.

Some key findings from this report...

• China is the world's most attractive destination for Pharma outsourcing based on an analysis of patient pools, cost efficiency, regulatory conditions, available expertise and infrastructure.

• There were 694,153 patent applications in China in 2007, a CAGR of 22.5% on the number of applications in 2003 (308,487). At this rate, China will be the world's largest patent-filing jurisdiction by 2012.

• China's service capabilities are strong, with full-scale medicinal chemistry services currently available from 26 CROs. Services include structure-based rational drug design, structure-activityrelationship (SAR)-based activity/potency optimization, and the optimization of pharmacological properties for lead compounds.

• In the next 3 to 5 years, the service capabilities of many China-based service providers will develop quickly and change the IP risk profile. Currently, the domestic industry is highly proficient in large-scale manufacturing but relatively weak in preclinical and clinical drug development, and as providers' capabilities increase the need for verification of effective IP protection protocols will intensify.

• The market will experience high growth of around 35% year on year to 2011. During this period, the industry will likely see investment in targeting, identification and validation capabilities.

Top reasons to order your copy today

• Understand how large pharma, small-sized pharma and biotech companies can benefit from the Chinese pharma market with this report's analysis of the number of companies involved, levels of industry maturity, and existing/projected service offering capabilities.

• Assess the the risk factors associated with outsourcing decisions and measure the suitability of China-based CROs and CMOs with this report's examination of each class of service provider and the key criteria for selecting the most appropriate company, including IPR protection protocols, service quality/capability, cost and geographic location.

• Understand how the IPR protection environment in China is evolving by evaluating the latest regulatory developments and patent application trends for domestic and multinational companies, in addition to this report's market forecasts for outsourcing industry growth to 2015.

• Identify how IPR protection varies across each stage of the R&D process and use case studies of partnerships between Chinese CROs/CMOs and Western companies to measure the success of recent endeavours.

Key issues examined in this report...

• Variable service offerings. Many Chinese pharma companies that have API manufacturing skills only offer their services on a seasonal basis. They are not professional CMO providers, as their service offerings are largely dependent upon spare production capacity levels.

• Inflated service claims. Although many CROs/CMOs claim a broad service scope to attract business, their actual service skills are limited to only a couple of areas. Specifically, scientific staff often lacks sufficient experience, training and deliverability guidelines.

• Inconsistent IPR protection system. IPR protection is no longer a serious issue amongst top-tier service providers but may still be weak in lower tier domestic companies and those operating in rural areas.

• IPR infringement cases and counterfeit drugs: Drug counterfeiting is still a real problem and most IPR infringement cases are related to trademark/copyright violations. However, there have been no reported cases of infringement of a western pharma or biotech's IPR by a Chinese company during their outsourcing collaborations.

Your questions answered...

• How does China compare to other outsourcing destinations?

• What services are offered by the CRO and CMO industry in China?

• What are the advantages of outsourcing different stages of the R&D process by large/small-sized pharma and biotech companies?

• What are the government's development priorities for the industry?

• How has medical infrastructure supported region-specific growth in outsourcing and will this trend continue?

• What is the strongest sector of China's pharma outsourcing industry in terms of both number of companies and strength of their services?

• Who are the major Chinese players in contract research and in which areas do they specialize?

• Which multinational companies have projects outsourced to China?

• What actions are the government taking to strengthen IPR protection?

Health Care Equipment & Supplies: Global Industry Guide

Fri, 20 Feb 2009 16:34:56 -0500

Datamonitor's Health Care Equipment & Supplies: Global Industry Guide is an essential resource for top-level data and analysis covering the health care equipment & supplies industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).

* Includes a five-year forecast of the industry

Highlights

The global health care equipment and supplies industry grew by 4.5% in 2007 to reach a value of $230.4 billion.

In 2012, the global health care equipment and supplies industry is forecast to have a value of $285.7 billion, an increase of 24% since 2007.

Sales of H/C supplies accounts for 40.4% of the industry's value.

The Americas region accounts for 45% of the industry's value.

Johnson & Johnson accounts for 9.4% of the industry's value.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The health care equipment & supplies industry consists of manufacturers of health care equipment and supplies.

Market value refers to the revenues generated through the sale of disposable equipment such as syringes, catheters, electrodes, sutures, bandages, implantable prostheses and orthotics and prosthetics; technical aids such as hearing aids and wheelchairs; ophthalmic equipment such as eye glasses, contact lenses and ophthalmoscopes; in vitro diagnostics such as devices for clinical chemistry, microbiology, immunology and genetic tests; and other equipment such as imaging equipment and films and equipment for radiotherapy, dialysis, endoscopy, anaesthetics, etc.

The market is valued at manufacturer's selling price with any currency conversions calculated using constant 2007 annual average exchange rates.

For the purpose of this report the Americas comprises Brazil, Canada, Mexico and the US.

Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and the UK.

Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan.

The global figure comprises the Americas, Asia-Pacific and Europe.

2009 Trends to Watch: Healthcare Technology

Fri, 20 Feb 2009 16:05:16 -0500

Introduction

Technology markets are changing fast. This brief is essential reading for you to identify the key forces shaping the prospects for your business. In this piece, Datamonitor's analyst specializing in healthcare technology will outline the changes in your market, explain which trends will have the biggest impact and highlight who will benefit from the developments in healthcare technology.

Scope

*An overview of challenges facing healthcare organizations in 2009

*Datamonitor's view of the technology priorities of providers and payers

*Strategies to help vendors in the healthcare technology market

Highlights

The healthcare industry is not immune to the global economic downturn

Governments are putting their money where their mouth is when it comes to quality of care

US stakeholders are eagerly awaiting Obama's plans for healthcare and healthcare IT

Reasons to Purchase

*Learn about the top trends in healthcare in 2009

*Gain insight into the technology areas healthcare organizations are investing in

*Identify strategies for expanding business opportunities in healthcare

The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Wed, 28 Jan 2009 14:48:31 -0500

The Cancer Market Outlook to 2013
Competitive landscape, pipeline analysis and growth opportunities
The market for cancer treatments is one of the largest and fastest growing areas in the pharma industry. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in the genomics, transcriptomics and proteomics sciences. Successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. More recently, biotech companies have been driving innovation in oncology more than ever before. Partnering with biotech companies is an important but expensive source of innovation for many pharma companies, with approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.
‘The Cancer Market Outlook to 2013' is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market's leading players are profiled. With coverage of over 90% of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2007-13 period are also provided.
Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this report...

Assess leading brands of treatment for each indication, identify potential growth opportunities and compare the outlooks of leading companies within the cancer market with this new report...

Some key findings from this report...
• Antineoplastic mAbs accrued sales of $11.3bn in 2007, amassing a market share of 34.1%. The most prominent contributors to market share in this class were MabThera (32.8%), Herceptin (28.8%), Avastin (25.2%) and Erbitux (10.2%). The total antineoplastics market is forecast to be valued at $43.0bn in 2013.
.• Amgen's blockbuster brands Neulasta (pegfilgrastim) and Neupogen (filgrastim) dominated the immunostimulant market in 2007, with sales of $3.5bn and $1.4bn respectively. Forecast sales for the immunostimulants market are estimated to reach $17.6bn in 2013.
• Roche is the leader in the global market for cancer treatments, with a market share of 34.9% (equivalent to $13bn sales) in 2007. Roche has recently bolstered its position through portfolio expansion, with the purchase of majority stakes in both Genentech and Chugai.
• A definitive merger between Eli Lilly and ImClone will increase Eli Lilly's flow of high-quality, innovative therapies. This will enable the company to offer physicians/patients a complementary portfolio of leading agents/targeted therapies including Gemzar, Alimta & Erbitux.
• Pfizer has a robust R&D pipeline with eight molecules in phase II and thirteen molecules in phase I, the highest among all the top ten companies in global cancer market.

Top five reasons to order your copy today
• Assess patient potential, treatment trends and sales patterns of major cancer indications over the period 2007-13, with this report's coverage of lung, breast, colorectal, ovarian cancer markets across Japan, France, Germany, Italy, Spain, the UK and the US.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of Roche, Amgen, Sanofi-Aventis, Merck KgaA, Novartis, Pfizer, Schering-Plough and Eli Lilly.
• Discover the market dynamics of the cancer area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting product development.
• Compare the cancer pipeline compounds of leading companies with this report's detailed analysis of clinically differentiated pipeline products by indication, in addition to sales forecasts for key R&D pipeline products in the global cancer market to 2013.
• Understand which indications are likely to generate franchise growth and examine major classes of cancer treatments including antineoplastics, immunostimulants and cytotoxic hormone therapies.

Key issues examined in this report...
• Reimbursement for cryoablation treatments. The new 2008 CMS rates for prostate cryoablation (in outpatient hospitals), under APC code 674, were raised from $6,685 to $7,816, an increase of 16.9%. The cryoablation rates for ambulatory surgical centers, known as ASC code 55873, were raised from $1,339 to $6,219, an increase of 364%.
• Plant-based cancer vaccine. Researchers are developing a plantbased vaccine which can be created more quickly and at far less expense than the animal-based version. The antibodies produced may also trigger a stronger immune response than in mammalian cells.
• Novel inhibitor of human microRNA. The Wistar Institute team have identified a small molecule that blocks the pathway of miR-21, which is implicated in brain cancer, as well as lung, colon, breast, and ovarian cancer. With further development, the molecule has the potential to boost patient response to existing chemotherapies.
• NICE guidance on kidney cancer drugs. The availability of high cost cancer drugs is one of the most pressing issues for the NHS. Drug makers are developing proposals which may reduce future drug costs.

Your questions answered...
• Which indications will experience the greatest growth in the global cancer market over the period 2008-13?
• How have recent major product launches from companies such as Roche, Amgen, Pfizer and Merck KGaA performed?
• What is the forecast market potential of the most exciting compounds currently in development for cancer indications?
• Which companies are best positioned for future success?
• What is the forecast market size and growth rate over the period 2007-2013 across the major cancer indications?
• How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of lung, breast, colorectal, ovarian, prostate, lymphoma and pancreatic cancer in 2013?

Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas

Wed, 28 Jan 2009 14:47:01 -0500

Introduction

In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development for the six tumor types are forecast to achieve $4,789m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.

Scope

*Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types

*Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions

*Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types

*Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights

Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and brivanib (BMS-582664; Bristol-Myers Squibb) show the most potential in the colorectal cancer pipeline. Aflibercept has shown activity following failure of prior standard Avastin (bevacizumab; Genentech/Roche), while brivanib's novel mechanism of action could represent a first-in-class therapy.

Melanoma is the most popular R&D target of the six tumor types covered in this report, due to persistent high unmet needs and a substantial incidence. Elesclomol (STA-4783; Synta Pharmaceuticals/GlaxoSmithKline) currently shows the most potential at present, although only if successful Phase II results can be replicated in Phase III studies.

First-line axitinib (AG-13736; Pfizer) and Gemzar (gemcitabine; Eli Lilly) showed similar response rates and overall survival to first-line Gemzar and Tarceva (erlotinib; Genentech/Roche) in pancreatic cancer. If this can be replicated in Phase III trials, approval is likely, given that Tarceva was approved based on a 2-week survival benefit.

Reasons to Purchase

*Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment

*Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to fulfil them

*Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

Forecast Insight: Depression - Generic induced brand erosion leads to market decline

Wed, 28 Jan 2009 14:44:54 -0500

Introduction

The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.

Scope

*This report gives a strategic analysis of the likely impact that recent events will have on the future depression market

*Includes depression-specific sales forecasts for the key brands, generics, and pipeline agents in the seven major markets to 2017

*Provides a global depression-market snapshot, and analysis of growth trends in key markets outside of the seven major pharmaceutical markets

*Conclusions are supported by key opinion leader comment

Highlights

Datamonitor has upgraded its depression-specific Abilify and Seroquel forecasts following positive clinical trial data in depression for both atypical antipsychotics, and the observation that regulatory approval of Abilify as an adjunct to antidepressants in depression resulted in an increase in the brand's quarterly sales growth rate.

Servier and Novartis's Valdoxan has emerged as the most promising pipeline depression drug following failure of several late-stage candidates. Prescribing for depression patients suffering from comorbid sleep disorders will drive sales over the forecast period.

Datamonitor forecasts moderate uptake of saredutant in refractory depression patients as an add-on therapy. While the drug failed to show efficacy as a monotherapy in clinical trials published over the last year, Sanofi-aventis is continuing to develop saredutant with two add-on therapy trials ongoing.

Reasons to Purchase

*Quantify the current size of the global major depressive disorder market

*Assess the impact of recent and anticipated events (patent expiries, new product launches, regulatory approval) on depression-specific brand sales

*Understand the country-specific impact of key events in the major depressive disorder market during the forecast period 2008 to 2017

Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets

Wed, 28 Jan 2009 14:43:27 -0500

Introduction

This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.

Scope

*Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia

*Fragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.

*Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.

Highlights

Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.

The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.

Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.

Reasons to Purchase

*Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.

*Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.

*Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor.